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S U M M A R Y
Nasopharyngeal (NP) pneumococcal carriage predisposes children to pneumococcal infections. Deﬁning
the proportion of pneumococcal isolates that are antibiotic-resistant enables the appropriate choice of
empiric therapies. The antibiogram of NP carriage isolates derived from a pediatric population following
the introduction of the 13-valent pneumococcal conjugate vaccine was deﬁned in this study.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Nasopharyngeal (NP) colonization by Streptococcus pneumoniae
predisposes young children to acute otitis media (AOM) and
invasive pneumococcal disease.1,2 The introduction of the seven-
valent pneumococcal conjugate vaccine (PCV7) in 2000 signiﬁcant-
ly increased the proportion of penicillin-susceptible pneumococcal
isolates (deﬁned as a penicillin MIC 0.06 mg/ml) isolated from NP
carriers in the pediatric population of St. Louis, Missouri, USA.3 The
deﬁnition of a high proportion of penicillin-susceptible isolates
conﬁrmed the appropriate use of low-dose amoxicillin (40-45 mg/
kg per day) as ﬁrst-line therapy for AOM in 2006.3,4 Recently the
American Academy of Pediatrics (AAP) has recommended ‘high-
dose’ amoxicillin (90 mg/kg per day) as ﬁrst-line therapy for AOM
because of increasing penicillin resistance.4 The new guidelines* Corresponding author. Tel.: +1 314 286 2136; fax: +1 314 286 2895.
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).posit that the 13-valent PCV (PCV13) may result in a reduced
prevalence of antibiotic resistance among disease-causing pneu-
mococcal isolates.4
A pneumococcal colonization prevalence study was performed
in the same geographic region as the 2006 study to evaluate trends
in penicillin resistance following the introduction of PCV13 in
2010. The objectives were to evaluate the prevalence of NP
pneumococcal colonization and to assess the antimicrobial
susceptibility proﬁles of pneumococcal isolates recovered.
2. Methods
Following approval by the Washington University Human
Research Protection Ofﬁce, informed consent for participation was
obtained from the parents/legal guardians of otherwise healthy
children aged 0–17 years requiring anesthesia for minor proce-
dures (e.g., herniorrhaphies) in the St. Louis Children’s Hospital
Same Day Surgery center.5 Children with a chronic illness, such as a
primary immunodeﬁciency or cystic ﬁbrosis, were excluded.
Children were also excluded if they were receiving an antibiotic,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Prevalence of nasopharyngeal pneumococcal colonization in children in the greater
St. Louis areaa
Age,
years
Enrolled Colonized
(%; 95% CI)
Penicillin MIC 0.06 mg/ml
(%; 95% CI)
<2 41 15 (37%; 24–52%) 8 (53%; 30–75%)
2–6 68 22 (32%; 22–44%) 10 (45%; 27–65%)
7 109 3 (2.7%; 1–8%)b 2 (67%; 21–94%)
Total 218 40 (18.3%; 14–24%) 20 (50%; 35–65%)
CI, conﬁdence interval; MIC, minimum inhibitory concentration.
a The numbers of children enrolled and colonized are shown, grouped by age.
Half of the nasopharyngeal isolates demonstrated penicillin MICs of 0.06 mg/ml.
Categorization of current isolates using the susceptibility criteria in use before
2006 allows direct comparison of the present ﬁndings to those reported previously
in our region.3
b Prevalence is signiﬁcantly lower in children aged 7 years than in children <7
years old; p < 0.0001.
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admitted to hospital within the preceding 24 h, or had been
enrolled previously. Vaccination coverage was determined by
obtaining records from primary care pediatricians.
A single NP swab (E-swab Minitip, Copan) was obtained, and eluate
(100 ml) was inoculated directly into 5% sheep blood agar plates (BAP;
BD Biosciences). To enrich for pneumococcus, 100 ml of eluate was
also inoculated into 3 ml Todd–Hewitt broth (BD Biosciences)
containing 0.5% yeast extract (THY) and 0.5 ml rabbit serum. After
incubation, 100 ml of inoculated broth was streaked directly onto BAP.
Following overnight incubation at 35 8C in 5% CO2, up to 12 a-
hemolytic colonies were selected for analysis. Gram-positive cocci in
pairs and chains were determined to be pneumococci if they were
catalase-negative, optochin-susceptible, and bile-soluble.3
Antibiotic susceptibility testing was performed in the Microbi-
ology Laboratory at St. Louis Children’s Hospital.6 The minimum
inhibitory concentrations (MICs) of penicillin and cefotaxime were
determined by gradient diffusion (Etest, bioMe´rieux). Susceptibil-
ities to erythromycin, clindamycin, sulfamethoxazole/trimetho-
prim, vancomycin, levoﬂoxacin, and linezolid were determined by
Kirby–Bauer disk diffusion.
Chi-square analyses were performed in GraphPad Prism.
Conﬁdence intervals (CI) were determined using the Wilson
procedure for calculating the 95% CI for a binomial proportion.
3. Results
During a 1-year period (July 2013 to June 2014), 218 children
were enrolled, of whom 40 (18.3%; 95% CI 14–24%) were colonized
with pneumococcus (Table 1). The prevalence of pneumococcal
colonization of children <2 years of age was 37% (95% CI 24–53%), of
children aged 2–6 years was 32% (95% CI 22–44%), and of children 7
years was 2.7% (95% CI 1–8%; p < 0.0001 by Chi-square test). The
overall prevalence of colonization in children aged 6 years or
younger was 34% (37 children colonized of 109 enrolled; 95% CI 26–
43%). There was no signiﬁcant correlation between receipt of three
or more PCV vaccines and colonization (data not shown).
The antimicrobial susceptibility proﬁle (antibiogram) of the
40 carriage isolates recovered was determined (Table 1, Figure 1
6,7). A statistically valid antibiogram requires a minimum of
30 isolates, as per guidelines established by the Clinical and
Laboratory Standards Institute.7 To enable direct comparison to
the earlier St. Louis study, the percentage of isolates with a
penicillin MIC 0.06 mg/ml was calculated (Table 1).8 There was
no signiﬁcant difference in penicillin susceptibility in the different
age groups, and it was found that 20 (50%; 95% CI 35–65%) of the
current isolates had a penicillin MIC of 0.06 mg/ml (Table 1).Figure 1. Percentage of nasopharyngeal colonizing and invasive isolates susceptible to
Institute guidelines6,7. PCN, penicillin; CTX, cefotaxime; ERY, erythromycin; CLI, clindam
meningitic breakpoint (PCN MIC 0.06 mg/ml, CTX MIC 0.5 mg/ml); NM, non-meningFinally, the antibiotic susceptibility proﬁles of the colonizing
isolates were compared to those of invasive pneumococcal isolates
recovered from clinical specimens (blood, cerebrospinal ﬂuid,
tracheal aspirates, and bronchoalveolar lavage specimens) at St.
Louis Children’s Hospital6 (Figure 1). The antibiotic susceptibility
proﬁle of colonizing isolates was similar to the 2012 and
2013 proﬁles of invasive isolates (Figure 1). The only signiﬁcant
difference between colonizing and invasive isolates was the
percentage of colonizing isolates that were penicillin-susceptible
under non-meningitic conditions using intravenous administra-
tion (PCN-S-NM; p = 0.038).
4. Discussion
The present study is consistent with other studies indicating
that PCV does not reduce the overall pneumococcal carriage
prevalence.1,2,9 It was found that the prevalence of pneumococcal
colonization in children under 7 years of age has not been reduced
from the prevalence of 39% identiﬁed in the prior study
(129 children colonized of 327 enrolled; 95% CI 26–43%).3 There
was also no increase in penicillin susceptibility following the
introduction of PCV13, as the proportion of isolates with a
penicillin MIC 0.06 mg/ml (50%) was lower than the proportion of
67% found previously.3 The stable prevalence of pneumococcal
colonization and unchanged proportion of isolates with a penicillin
MIC 0.06 mg/ml were observed even though the study popula-
tions were slightly different; children with symptoms of an upper
respiratory infection (URI) were excluded in the present study,
while they were included in the prior study.3 As URI symptoms are
a risk factor for pneumococcal colonization,2 a lower prevalence in
the present study might have been expected based on this the antibiotics indicated, deﬁned in the 2014 Clinical and Laboratory Standards
ycin; SXT, sulfamethoxaxole/trimethoprim; VA, vancomycin; LZD, linezolid; MEN,
itic breakpoint (PCN MIC 2 mg/ml, CTX MIC 1 mg/ml).
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those of recent studies performed in Israel and Atlanta, Georgia,
USA, in which receipt of PCV13 increased the proportion of
penicillin-susceptible isolates among colonizing isolates.2,10 Colo-
nizing isolates found in St. Louis were also more resistant to
penicillin than those in a recent cross-sectional study performed in
Milan.1 Higher penicillin MICs of NP pneumococci in St. Louis
compared to those in other areas may be due to greater antibiotic
use in the USA, although conﬁrmation of a causal relationship
requires further study.
With the exception of a slightly higher prevalence of b-lactam-
susceptible colonizing isolates, the antibiotic susceptibility proﬁles
of colonizing isolates closely approximate those of invasive
isolates, demonstrating that population surveys of colonizing
isolates can be used to determine the local choice of empiric
antibiotic therapy.
In summary, the prevalence of pneumococcal colonization in
the pediatric population of the St. Louis area was surveyed, ﬁnding
no change in prevalence and, more importantly, no evidence of an
increasing prevalence of penicillin-susceptible isolates following
the introduction of PCV13.
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